Evolving Strategies in the Treatment of HER2-positive Metastatic Breast Cancer with Antibody-Drug Conjugates and Tyrosine Kinase Inhibitors – Enduring Webcast

Description

Program Description

---

HER2 is overexpressed in approximately 20% of all breast cancers. Before the development of HER2-directed monoclonal antibodies, HER2-positive breast cancer was associated with a relatively poor prognosis. With the advent of monoclonal HER2-targeting antibodies (trastuzumab and pertuzumab) and antibody-drug conjugates (trastuzumab emtansine [T-DM1] and trastuzumab deruxtecan), clinical outcomes for HER2-positive breast cancer have dramatically changed, and a more significant proportion of patients in the nonmetastatic setting are cured. However, in the metastatic setting, resistance to anti-HER2 treatments remains a major therapeutic challenge, underscoring the importance of developing novel HER2-directed therapies. Over the last year, there has been a dramatic shift in the current treatment paradigms for HER2-positive metastatic breast cancer, with recent U.S. Food and Drug Administration approvals of trastuzumab deruxtecan (DS-8201), neratinib, and tucatinib in combination with trastuzumab and capecitabine.

Intended Audience

---

This webcast is designed to meet the educational needs of hematologists/oncologists, nurse practitioners, physician assistants, and nurses involved in the care and treatment of patients with HER2-positive breast cancer.

Commercial Supporter

---

This activity is supported by an educational grant from Seagen Inc.